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Giulia Saraconi, Francesco Severi, Cesare Sala, Giorgio Mattiuz and Silvestro G Conticello*Erratum
During the typesetting of the final version of the article
[1] some data in Table 1 have been accidentally changed.
These data were correct in the provisional version of the
article. A correct Table 1 is as follows:
Please note that references 41 and 42 in the table
legend correspond to the reference order in the ori-
ginal article [1].
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Table 1 List of the non-clonal mutations identified in theBCR-ABL1 fusion gene from imatinib-resistant K562 clones
Samples Position AA change Codon change Sequence context
Control 1409 E495G GAA > GGA
1472 R491Q CGG > CAG GCCGG
1503 Silent TTT > TTC
AID 298 G100C GGC > TGC GCCTA
395 Silent AAA > AAG
568 G190D GGC > GAC TGCCA
633 T212A ACG >GCG
Rat APOBEC1 344 G155D GGC > GAC GGCCA
607 L203M CTG > ATG CCCTG
613 E205K GAG > AAG CTCGG
764 K255T AAG > ACG
987 Silent GGG > GGT TTCCC
Human APOBEC1 669 Silent AGC > AGT AGCCG
758 R253H CGC > CAC TGCGC
841* Silent CTG > TTG AGCTG
697 H233D CAT > GAT TTCAT
699 H233D CAT > GAC
1149* Silent GCC > GCA GCCAT
1245* F415L TTT > TTG
The region analyzed (encompassing exon 13 of BCR and exon 9 of ABL1) includes the imatinib-binding region of the fusion gene. The asterisk indicates mutations
found in the same clone. The local sequence context for the mutations at cytosines is shown. Compared to the AID-induced mutations found in previous reports
(mutations in approximately 30% of the sequences) [41], [42], we found approximately one mutation in each of the clones analyzed. This is explained by the different
procedures we used to select resistant clones: whereas the other studies focused on competing bulk populations of AID-transfected GFP(+) cells and control GFP(−) cells,
we analyzed individual clones arising from the same number of cells plated in the presence of imatinib.
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